title: Transcriptional profiling and network analysis of the murine angiotensin II-induced abdominal aortic aneurysm.
abstract: We sought to characterize temporal gene expression changes in the murine angiotensin II (ANG II)-ApoE-/- model of abdominal aortic aneurysm (AAA). Aortic ultrasound measurements were obtained over the 28-day time-course. Harvested suprarenal aortic segments were evaluated with whole genome expression profiling at 7, 14, and 28 days using the Agilent Whole Mouse Genome microarray platform and Statistical Analysis of Microarrays at a false discovery rate of <1%. A group of angiotensin-treated mice experienced contained rupture (CR) within 7 days and were analyzed separately. Progressive aortic dilatation occurred throughout the treatment period. However, the numerous early expression differences between ANG II-treated and control were not sustained over time. Ontologic analysis revealed widespread upregulation of inflammatory, immune, and matrix remodeling genes with ANG II treatment, among other pathways such as apoptosis, cell cycling, angiogenesis, and p53 signaling. CR aneurysms displayed significant decreases in TGF-β/BMP-pathway signaling, MAPK signaling, and ErbB signaling genes vs. non-CR/ANG II-treated samples. We also performed literature-based network analysis, extracting numerous highly interconnected genes associated with aneurysm development such as Spp1, Myd88, Adam17 and Lox. 1) ANG II treatment induces extensive early differential expression changes involving abundant signaling pathways in the suprarenal abdominal aorta, particularly wide-ranging increases in inflammatory genes with aneurysm development. 2) These gene expression changes appear to dissipate with time despite continued growth, suggesting that early changes in gene expression influence disease progression in this AAA model, and that the aortic tissue adapts to prolonged ANG II infusion. 3) Network analysis identified nexus genes that may constitute aneurysm biomarkers or therapeutic targets.
authors.affiliation: Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford, CA 94305, USA. jspin@cvmed.stanford.edu
authors.forename: Joshua M
authors.initials: JM
authors.lastname: Spin
authors.forename: Mark
authors.initials: M
authors.lastname: Hsu
authors.forename: Junya
authors.initials: J
authors.lastname: Azuma
authors.forename: Maureen M
authors.initials: MM
authors.lastname: Tedesco
authors.forename: Alicia
authors.initials: A
authors.lastname: Deng
authors.forename: Justin S
authors.initials: JS
authors.lastname: Dyer
authors.forename: Lars
authors.initials: L
authors.lastname: Maegdefessel
authors.forename: Ronald L
authors.initials: RL
authors.lastname: Dalman
authors.forename: Philip S
authors.initials: PS
authors.lastname: Tsao
mesh_terms: D000804:Angiotensin II / Q000494:pharmacology*; D000818:Animals; D017544:Aortic Aneurysm, Abdominal / Q000139:chemically induced* / Q000235:genetics / Q000378:metabolism*; D001057:Apolipoproteins E / Q000235:genetics / Q000378:metabolism; D007150:Immunohistochemistry; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D020411:Oligonucleotide Array Sequence Analysis
chemical_list: D001057:Apolipoproteins E; D000804:Angiotensin II